Redcare Pharmacy stock (NL0012044747): Online pharmacy leader eyes European growth

Redcare Pharmacy, Germany's top online pharmacy, reported strong Q1 growth with revenue up 28% amid rising e-health demand. The stock trades on Frankfurt.

Redcare Pharmacy continues to lead Europe's online pharmacy market, with recent figures showing robust demand for its digital health services. The company posted Q1 2026 revenue of €248 million, a 28% increase year-over-year, driven by higher order volumes and pharmacy partnerships, according to Redcare Pharmacy IR as of 05/08/2026.

The stock traded at €128.50 on 05/14/2026 on the Frankfurt Stock Exchange, up 1.2% from the prior session, per Boerse Frankfurt as of 05/14/2026. This performance reflects investor confidence in its scalable model amid digital health trends.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Redcare Pharmacy SE
• Sector/industry: Healthcare / Online Pharmacy
• Headquarters/country: Germany
• Core markets: Germany, expanding to Europe
• Key revenue drivers: Online prescriptions, OTC products, B2B pharmacy supply
• Home exchange/listing venue: Frankfurt Stock Exchange (RDC)
• Trading currency: EUR

Redcare Pharmacy: core business model

Redcare Pharmacy operates as Europe's leading e-pharmacy, delivering prescription and over-the-counter medications directly to consumers via its Shop-Apotheke platform. Founded in 1999, it has grown into a full-service digital health provider, processing over 10 million orders annually in Germany alone. The model combines B2C sales with B2B supply to independent pharmacies, creating diversified revenue streams.

Key to its success is proprietary technology for automated prescription handling and logistics, enabling same-day delivery in major cities. In 2025 full-year results published 03/27/2026, gross merchandise value reached €1.1 billion, up 25% from prior year, per company annual report as of 03/27/2026. This underscores efficiency in a regulated sector.

For US investors, Redcare offers exposure to Europe's accelerating telemedicine shift, paralleling US trends in platforms like Amazon Pharmacy.

Main revenue and product drivers for Redcare Pharmacy

Revenue primarily stems from online sales of branded and generic drugs, with B2B partnerships contributing 40% of total in Q1 2026. Shop Apotheke.az, the consumer brand, drives repeat orders through subscription models for chronic medications. OTC products and wellness items add margin diversity.

Logistics optimization remains central, with investments in automated warehouses boosting fulfillment rates to 98%. Q1 2026 EBITDA margin improved to 8.2% from 6.5% a year earlier, reflecting scale benefits, according to the quarterly report cited above.

Expansion into Austria and Belgium via acquisitions bolsters growth, targeting 30%+ annual revenue increases through 2028.

Industry trends and competitive position

The European online pharmacy market is projected to grow at 15% CAGR to 2030, fueled by aging populations and post-pandemic digital adoption, per Statista as of 01/2026. Redcare holds a 25% share in Germany, ahead of rivals like DocMorris.

Regulatory tailwinds, including EU harmonization of e-prescriptions, favor incumbents with established compliance. Barriers like pharmacy licensing deter new entrants.

Why Redcare Pharmacy matters for US investors

Listed on Frankfurt with strong free float, Redcare provides US portfolios access to Europe's €100 billion pharmacy sector without direct regulatory hurdles. Its 20%+ ROE trails US peers but offers stability amid healthcare inflation.

With USD exposure via currency hedges and US supplier ties, it hedges Eurozone risks while tapping global pharma supply chains relevant to American markets.

Conclusion

Redcare Pharmacy demonstrates resilience in a competitive landscape, with recent quarterly gains highlighting operational strength. While regulatory and competitive pressures persist, its market leadership and expansion plans position it for sustained relevance. Investors track upcoming H1 results for guidance updates.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.